[{"id":"d0c7acc3-5f08-4014-b6ae-dd852fb3d748","acronym":"","url":"https://clinicaltrials.gov/study/NCT04304040","created_at":"2021-01-18T20:52:28.941Z","updated_at":"2024-07-02T16:35:20.402Z","phase":"Phase 1/2","brief_title":"A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma","source_id_and_acronym":"NCT04304040","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib) • obinutuzumab-β (MIL62)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-02-07"},{"id":"3c0eb7a3-b4bf-497f-92bf-f74620c8fe95","acronym":"","url":"https://clinicaltrials.gov/study/NCT04834024","created_at":"2021-04-06T11:55:34.331Z","updated_at":"2024-07-02T16:35:32.472Z","phase":"Phase 3","brief_title":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma","source_id_and_acronym":"NCT04834024","lead_sponsor":"Beijing Mabworks Biotech Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • obinutuzumab-β (MIL62)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 06/02/2021","start_date":" 06/02/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-10-20"},{"id":"a9a2b5ea-c53f-4b28-aa66-0e3b0cbbc887","acronym":"","url":"https://clinicaltrials.gov/study/NCT04110301","created_at":"2021-01-18T20:05:55.123Z","updated_at":"2024-07-02T16:35:32.388Z","phase":"Phase 1b/2","brief_title":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","source_id_and_acronym":"NCT04110301","lead_sponsor":"Beijing Mabworks Biotech Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • obinutuzumab-β (MIL62)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 11/28/2019","start_date":" 11/28/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-10-20"},{"id":"449356da-d3de-4f7e-afad-1d83e9f3008c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04103905","created_at":"2021-01-18T20:04:19.112Z","updated_at":"2024-07-02T16:36:29.011Z","phase":"Phase 1","brief_title":"A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas","source_id_and_acronym":"NCT04103905","lead_sponsor":"Beijing Mabworks Biotech Co., Ltd.","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e obinutuzumab-β (MIL62)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 02/10/2017","start_date":" 02/10/2017","primary_txt":" Primary completion: 05/30/2019","primary_completion_date":" 05/30/2019","study_txt":" Completion: 05/29/2020","study_completion_date":" 05/29/2020","last_update_posted":"2021-06-16"}]